Numerous countries are facing oxygen shortages, while readily available oxygen products are in short supply.

As some 32 countries worldwide, including seven African nations, face “code red” oxygen shortages, WHO and its partners are in the midst of a major effort to recruit sufficient supplies to meet countries’ urgent needs for life-saving oxygen.  

But while over US$500 million is now available in funds and finance for oxygen through the Access to COVID-19 Tools (ACT) Accelerator initiative, many African countries at risk of oxygen shortages have yet to apply for available funding to bolster their oxygen supplies – including Algeria, South Africa and the Democratic Republic of Congo.  

Delays in asking for funding, or asking for the wrong mix of supplies, can make response to oxygen demand surges an even bigger challenge, warned experts at an event Thursday co-organised by Unitaid, Waci Health, and the Every Breath Counts partnership, a coalition of UN agencies, businesses, donors and NGO.

They urged countries to fine-tune requests and accelerate their applications to meet the next deadline for financing requests – as well as to fine-tune demands to ensure a faster and more flexible response to shortages – including a “very dire” situation in some African nations.

‘Very dire’ situation in Africa

Globally 70 countries are at risk of oxygen shortages. Surges in COVID cases – due in large part to the Delta variant (B.1.617.2) – and hospitalizations are overwhelming health systems and driving up deaths.  

Among the African countries facing dangerous levels of oxygen shortages are: Ethiopia, Nigeria, Ghana, Benin, Togo, Cote d’Ivoire, and Somalia. Meanwhile, Somalia and nine other African at-risk countries have yet to even apply for funding for oxygen supplies. They include: Algeria, Libya, Mauritania, Guinea, the Democratic Republic of Congo, South Africa, eSwatini, Mozambique, and Botswana. 

As a result of health systems lacking oxygen and other supplies needed to manage serious COVID cases, the African region is also witnessing “worrying mortality trends,” according to WHO. Last week eight African countries reported increases of over 50% in weekly deaths.

“[There are] large and critical surges in the need for oxygen and too many unacceptable deaths [have been] associated with the lack of access to it,” said Robert Matiru, Director of Programmes at Unitaid, at the event.

Robert Matiru, Director of Programmes at Unitaid, at an event on Thursday co-organized by Unitaid, Every Breath Counts, and Waci Health.

“Medical grade oxygen is one of the most critical medicines for people with severe and critical COVID-19…but unfortunately it is not something that is readily available,” said Dr Raji Tajudeen, Head of the Division of Public Health Institutes and Research at Africa Center for Disease Control and Prevention (CDC). “When oxygen is available, the cost is prohibitive.”

Financing requests exceed available oxygen supplies 

The ACT-Accelerator’s COVID-19 Oxygen Emergency Taskforce, which was launched in February, has mobilised over US$340 million for oxygen-related products in low- and middle-income countries (LMICs) through the Global Fund’s COVID-19 Response Mechanism (C19RM)

In addition, some US$182 million has been donated to the therapeutics pillar of UNICEF’s Access to COVID-19 Tools Accelerator Supplies Financing Facility (ACT-A SFF). The finance mechanism is dedicated to the procurement and delivery of therapeutics for LMICs, including oxygen. 

But while this represents significant progress toward ACT-A’s goal of raising US$1.2 billion for COVID oxygen needs – bottlenecks in the manufacture of oxygen cylinders and long lead times required for the construction of large-scale pressure swing absorption (PSA) oxygen generating plants are delaying the acute deployment of crisis support, officials said. 

Challenges faced by the Access to COVID-19 Tools (ACT) Accelerator’s COVID-19 Oxygen Emergency Taskforce to address the immediate demand surges in oxygen.

“Even though it’s really encouraging news that we have almost US$340 million awarded, we don’t have enough supply to meet that once procurement and delivery actually begin,” said Robert Matiru, Director of Programmes at Unitaid, at the event on Thursday.

“That is why it’s really critical to already be putting in place interventions to accelerate procurement and delivery and also medium-term measures to ensure that these lead times are cut dramatically for subsequent suppliers and awards,” he added.

Countries urged to fine-tune demands & prioritise oxygen sourcing options that could accelerate access

A breakdown of the approved funding requests from the Global Fund’s COVID-19 Response Mechanism (C19RM).

He urged countries to fine-tune their oxygen supply plans and finance requests accordingly – by considering a wider range of oxygen supply options.

Rather than prioritizing the construction of new PSA facilities, which take a long time to build, countries should consider alternatives like the repair of existing PSA systems, and procurement of bulk liquid oxygen supplies, Matiru said.

“Once you have massive surges, you really need a larger generation capacity and a larger supply capacity than PSA can provide,” said Matiru. 

Procurement of liquid oxygen, which can be stored in bulk at facilities or converted to oxygen cylinders for delivery, may be the fastest way to increase oxygen supply in countries that have existing supply lines for deliveries, he said.

Repairing existing PSA plants may also be more cost-effective and faster than constructing new facilities, as new plants can cost up to US$250,000 and take three to 12 months to complete. 

Algeria, DRC, South Africa and other countries yet to apply for oxygen support finance

In addition, more LMICs should be encouraged to apply for funding for oxygen supplies through the Global Fund’s COVID-19 Response Mechanism, said Matiru.

The deadline to submit the financing request is fast approaching on 17 September, he warned, urging countries to meet it.

Officials from organisations on the ACT-A taskforce also said that there was room for improvement among partners in their coordination of efficient procurement and delivery services. 

“We know as a taskforce we need to be more effective as partners to more effectively attract demand, financing, technical cooperation, and supply, so that we can ensure tight coordination, avoid duplication and be efficient with these resources that are being channelled at unprecedented rates in countries,” said Matiru.

Building local technical and manufacturing capacity – avoiding ‘white elephants’

Along with increasing the supply of oxygen products, building technical capacity and human capital is essential for the sustainable continuation of oxygen infrastructure, said the experts. 

Investing in the health workforce, and expanding biomedical human capital in member states, is important for the service and maintenance of oxygen services and facilities. 

“This unprecedented amount of equipment and supplies has to be maintained and sustained,” said Matiru. “We can’t afford to have white elephants and not sustain the benefit of these investments through this pandemic and even beyond this pandemic for the critical needs we know are out there and predated this pandemic: childhood pneumonia, trauma, complications in childbirth, sepsis and so on.”

One of the key steps moving forward is investing in local manufacturing capacity and developing a “new public health order” in Africa, said Tajudeen.

Dr Raji Tajudeen, Head of the Division of Public Health Institutes and Research at Africa Center for Disease Control and Prevention (CDC).

“To guarantee continental health security, we cannot continue to rely on importation of [oxygen products] from the outside,” Tajudeen said. 

“We know that with new COVID-19 waves there will definitely be new variants,” he added. “And with the low level of vaccine coverage on the continent, we need to continue to make the case for the investment in medical grade oxygen.” 

Some 2.8% of the African population are fully vaccinated, compared to 47.7% in Europe and 42.3% in North America. 

“Going forward [we] really need to begin to look at investing in an oxygen infrastructure so that people with severe COVID and those who…cannot afford oxygen will be able to have access to this oxygen,” said Tajudeen.

Image Credits: WHO/Blink Media – Nada Harib, UNICEF/Ralaivita, Unitaid.

Funeral pyres in Uttar Pradesh

Most people die at home in Gadchiroli, a remote, heavily forested district in central India that is among the country’s least developed areas and reaching the nearest clinic can take several hours on foot. 

After a death, relatives often bury or cremate their loved ones in the fields.

When the first COVID-19 wave arrived in India in 2020, it barely reached Gadchiroli. But in April 2021, as a devastating second wave tore through rural India, people began getting sick.

Yogesh Kalkonde, a public health doctor and researcher who worked with the non-governmental organization Search in Gadchiroli until July, said he soon began hearing about deaths in villages – sometimes four or five in a single small community. 

People seriously ill with COVID-19 began turning up at his rural hospital. But Kalkonde said he had little way of gauging the extent of the outbreak.

Similar situations were playing out in other parts of India. While official figures recorded averages of around 3,000 or 4,000 COVID-19 deaths per day, analysts saw signs that mortality across the country was far higher. But they struggled to produce even rough estimates of the true toll. 

Indeed, experts say that the pandemic has highlighted a longstanding issue: In the world’s second-most populous country, policymakers have historically paid too little attention to tracking people’s deaths, with serious implications for public health.

In fact, more than 100 countries do not have functioning civil registration and statistics systems that record births and deaths, according to the public health organisation Vital Strategies

Several African countries collect little or no data on deaths, and the World Health Organization estimates that, globally, two-thirds of deaths are never accounted for.

Rural areas account for three-quarters of deaths 

Rural India, where deaths are often unrecorded.

These issues are acute in India, which is home to about one in six of the world’s people, and where around three-quarters of deaths take place in rural areas like Gadchiroli. 

In 2018, government surveys suggest that India registered 86 percent of all its deaths in its civil registration system. Even then, the cause often remains a mystery: Only one in five of those registered deaths were medically certified by a physician.

Those gaps, experts say, hampered public health efforts in India and other countries long before the arrival of COVID-19. Governments can use death data for all sorts of public health decisions: to identify malnutrition hotspots, address infant mortality, and even prioritize the shipment of vaccines.

“Counting the dead helps the living,” said Prabhat Jha, an epidemiologist at the University of Toronto and director of the Center for Global Health Research, a not-for-profit organization co-sponsored by the university and St. Michael’s Hospital. 

“The main benefit of having data on who dies, and when, is to be able to understand what can be done about it today.”

While counting the dead is the first step, finding out how they died is also key. Cause of death data is like the “thermometer of a health system,” said Kalkonde. Without such data, he added, it is very challenging to track the progress of the health system.

Experts say the obstacles to improving data collection in India are steep. And even when such data exist, that doesn’t mean they will be accurate and available to the public — or to health researchers. Public health doctor and researcher Sylvia Karpagam said she doesn’t expect much government effort to discover and publicize the real toll of COVID-19.

“Right now, it is all about making the government look good, and it is more about PR,” she said. The country’s leaders, she added, “wouldn’t want to seriously look at how many people died.”

The government’s Ministry of Health and Family Welfare, refuting such criticism from activists and the media, said in an official statement in August that the suggestion that it was “missing out on deaths is completely unlikely.” 

The government’s Office of the Registrar General and Census Commissioner did not respond to requests for comment.

Little incentive to report deaths

Each year, 9.7 million people die in India, according to government statistics – more than the entire population of New York City. Those deaths are scattered across a country with 23 officially recognized languages, nearly 600,000 villages, and a severe shortage of medical personnel. Keeping track of those losses in areas without a functioning health care system is a difficult, but not insurmountable, task.

In large cities like Mumbai or Delhi, most deaths occur at, or en route to, a health facility. If a physician is present at the time of death, they fill out a cause of death certificate. Local authorities collect this information and pass it on to the state and then national government.

Far fewer deaths are certified in rural areas like Gadchiroli, where health facilities are bare or virtually non-existent. Complicating the data collection, rural people often have little incentive to report deaths. Birth documentation is an important part of one’s legal identity, enabling access to services like education. But for those with few resources, living in places where informal transfer of property is the norm, there’s little reason to report deaths to authorities, especially of babies.

Gender and social status also affect which deaths are counted: Women, for example, are more likely to die at home, and less likely to have their deaths counted and certified, according to Kalkonde. And people who belong to India’s tribal communities, or who fall low in the Hindu caste hierarchy, typically have less access to health care, and so show up less frequently in official statistics.

There is little incentive to record deaths in rural India, where people own little and property ownership is usually transferred informally.

Dubious data

Then there is the dubious quality of data. Not all doctors are well trained to certify deaths, said Kalkonde. “What you write on death certificate in itself is a science,” he said. 

“So, even amongst the death certificates that are available, many times the cause of death is just listed as ‘cardiorespiratory arrest’” — meaning the person’s heartbeat and breathing stopped. “I mean, most of us die by cardiorespiratory arrest,” Kalkonde added.

To account for some of these gaps, in the 1960s the Indian government began sending surveyors door to door in thousands of areas across the country, in order to get a representative sample of the full population. 

When a selected household reports a recent death, the surveyor gathers the history of illnesses in the family, asks about the deceased person’s symptoms, and writes a report. Trained physicians look over the record and assign it a probable cause of death. Research suggests that this time-consuming process, called a verbal autopsy, provides a fairly accurate picture of the deaths. (China, the world’s most populous country, uses a similar system.)

In 2002, Jha and several collaborators began tracking mortality in 2.4 million households in India, using verbal autopsies to assign causes for deaths going back to 1998. The Million Death Study, as it is called, was far larger than other surveys, and its findings helped provide crucial insight into deaths by suicide, infant and child mortality, cancer in India, and more.

Still, researchers say, big gaps remain in the data. “It’s strange that, you know, 70 years down the road,” said Kalkonde, referring to the time since India’s independence, “we still have difficulty knowing what are the causes of death in India.”

High suicides in women

Government officials aren’t always especially eager to publicize mortality data. Registering and certifying all deaths allows for accountability that leaders might not want, said Karpagam.

The findings of such studies don’t always align with state narratives about an accepting, egalitarian culture. Verbal autopsies have suggested, for instance, that one in every three women who die by suicide globally is an Indian woman.

In response, health officials and politicians sometimes hide or fudge statistics: Independent analysts and news media have found that officials in the state of Maharashtra have downplayed the number of malnutrition-linked deaths, and policymakers have delayed — and even allegedly hidden — statistics on deaths by suicide among India’s farmers.

Those problems have worsened since 2014, Jha said. Since then, when the current prime minister Narendra Modi came to power, there have been more delays in releasing India’s sample survey. Recent years have also seen delays in farmer death statistics.

“Many times the cause of death is just listed as ‘cardiorespiratory arrest’” – meaning the person’s heartbeat and breathing stopped. “I mean, most of us die by cardiorespiratory arrest,” Kalkonde said.

COVID-19 exposed gaps

When a massive second wave of the pandemic hit India in the spring of 2021, the shortcomings of these gaps in mortality data were suddenly on display, as there was hardly any accounting of how many people in India’s rural areas were dying from COVID-19. The data disaster made global headlines.

In response, some Indian states have begun conducting door-to-door surveys, trying to pin down more accurate figures. Others released revised death statistics after courts stepped in to flag irregularities.

The solution to the improving reporting of death data is different in urban and rural areas, Jha said. “In urban areas many deaths occur in hospitals, so you can improve that registration and reporting system,” he said. In rural areas, he added, some of the villages already track deaths. “I think that’s important, but that needs to be catalogued and shared.”

Women are far likelier to die at home in rural India

Death records helped to counter vaccine hesitancy

A treacherous 10-hour drive along winding mountain roads northwest of Gadchiroli is the tribal region of Melghat. Deep in the forests, the phone network sometimes drops to zero. Melghat is known for its tiger reserve. It’s also poor: The region occasionally makes news for the high rate of child malnutrition deaths among its largely tribal population, spread across about 370 villages.

Mittali Sethi came here on her first government posting, part of a national cadre of civil servants called the Indian Administrative Service. Until transferring to a new position in July, Sethi, a trained dental surgeon, was in charge of the development of the tribal population, including overseeing health programs.

According to Sethi, there is one private physician in Melghat and a handful of government ones. For specialized medical care, she says, locals have to leave the district and travel around three hours in a vehicle to a facility in the nearest city, Amravati.

Here Sethi put into practice what Jha recommends in theory. Through a national programme  launched in 2005, India’s villages have an army of women community health care workers called Accredited Social Health Activists, or simply ASHAs, which in Hindi translates to “hope.” Often working in their home villages, these women are trained in basic health care delivery, like providing pregnant women with iron and folic acid tablets, and helping with awareness campaigns on sanitation.

As the second COVID-19 wave arrived in April, Sethi reached out to the ASHAs in Melghat and asked the women to report every death to their nearest health center on a daily basis, along with the likely cause.

“We were monitoring which village was having more deaths, because people were a little reluctant to test,” Sethi said. “So the proxy for knowing where COVID-19 might actually be increasing was to see the number of deaths.”

This basic data was enough to give Sethi and her team information about where to step up COVID-19 awareness and vaccination campaigns. “Not having data has never been a problem here,” she said. The resultant campaigns were successful in countering vaccine hesitancy and made national news in India.

What Sethi did in Melghat is what Jha said could be done in every district in India. The approach essentially decentralizes the health system, gathering and responding to data in real-time instead of waiting for a national level analysis.

“The proxy for knowing where Covid might actually be increasing was to see the number of deaths,” Sethi said.

As other countries grapple with similar problems, experts are hoping the pandemic will draw attention to death registration. Having better data, the WHO writes in a new report on global birth and death registration, would help communities around the world combat COVID-19 — and forms “a cornerstone of a strong health system for the future.”

Romain Santon, deputy director of civil registration and vital statistics for Asia at Vital Strategies, which has helped 29 countries bolster their civil registration systems, said simple policy changes can yield better data. In some countries, he said, burial permits or other legal requirements could act as incentives to push up death registrations. Making registration simpler by reducing the number of forms, or digitizing the process, could also help.

Santon calls for compulsory, confidential, and permanent death registration worldwide. “Every single individual living in a territory,” he said, “should have access to birth and death registration.”

Disha Shetty is an independent science journalist based in Pune, India. She writes on health, environment, and gender, among other subjects. This article was first published in UnDark

 

Image Credits: Parker Hilton/ Unsplash, Tarun Anand/ Unsplash, Aditya Siva/ Unsplash, Yogendra Singh/ Unsplash.

Only a quarter of countries worldwide have a national plan to support people with dementia and their families, according to the World Health Organization’s (WHO)  ‘Global status report on the public health response to dementia’ released on Thursday. 

More than 55 million people globally are living with dementia and the number is estimated to increase by almost 40% to 139 million by 2050,  according to WHO.

While most countries have made progress in implementing public awareness campaigns to improve public understanding of dementia, only a quarter of countries have a national policy, strategy or plan for supporting people with dementia and their families, prompting WHO to call for renewed commitment from governments. 

Half the countries with national policies, strategies or plans are in WHO’s European Region, yet even in Europe, many plans are expiring or have already expired.

The COVID-19 pandemic has also resulted in “profound” disruption for people living with dementia, including hampering dementia risk reduction programmes.

“The world is failing people with dementia, and that hurts all of us,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “ Four years ago, governments agreed on a clear set of targets to improve dementia care. But targets alone are not enough. We need concerted action to ensure that all people with dementia are able to live with the support and dignity they deserve.”

WHO’s Western Pacific Region has the highest number of people with dementia (20.1m), followed by the European Region (14.1m), the Region of the Americas (10.3m), the South-East Asia Region (6.5m), the Eastern Mediterranean Region (2.3 m) and the African Region (1.9m). 

If left unaddressed, the increase would significantly undermine social and economic development globally, warned Tedros.

Dementia is caused by a variety of diseases and injuries that affect the brain, including Alzheimer’s disease or stroke. It affects memory and other cognitive functions, as well as the ability to perform everyday tasks.

In 2019, 1.6 million dementia-related deaths were recorded, making it the seventh leading cause of death. Nearly half of these deaths occurred in high-income countries with women representing roughly 65% of the total number of dementia-related deaths.

The global cost of dementia was estimated to be $1.3 trillion in 2019,  projected to increase to $1.7 trillion by 2030, or $2.8 trillion if corrected for increases in care costs. 

“A challenge of this size cannot be tackled by working in silos. We must combine forces, improve the capacity of health systems to prevent and treat dementia, share quality data, reach beyond our traditional ways of conducting research, and address dementia as a global community,” said Dévora Kestel, WHO Director Department Mental Health and Substance Use.

“Dementia robs millions of people of their memories, independence and dignity, but it also robs the rest of us of the people we know and love,” said Dr Tedros.

COVID-19 and dementia

In addition to the high number of COVID-19 deaths in long-term care facilities, some countries reported unexplained increased numbers of deaths among people with dementia. England and Wales recorded 83% more deaths in people with dementia in April 2020.

“These increased deaths reported in 2020 may be due to factors such as interruptions in routine care, breaks in medication supply chains and resultant medication stock-outs, decreased access to emergency services, and the psychosocial impacts of public health measures designed to control the pandemic,” states the report.

It highlights numerous barriers that impede the progress of dementia reduction including stigma and the lack of public awareness of its importance, lack of financial resources available for dementia risk reduction programmes, inequitable distribution of services, human resource limitations, and lack of coordination between sectors both nationally and locally. 

In terms of COVID-19’s impact on dementia carers, the report found that lockdowns limited the services offered to people living with dementia resulting in delayed access to diagnostic and post-diagnostic care and a significant impact on cognitive health.

Urgent need for more support 

A stand-out finding of the report is the urgent need to strengthen support, of care for people with dementia, and in support for the people who provide that care, in both formal and informal settings.

Some 75% of primarily high-income countries reported that they offer some level of support for carers – carers spent on average five hours a day caring for those suffering from dementia, with 70% of care being provided by women.

Dementia sufferers require various degrees of care including primary health care, specialist care, community-based services, rehabilitation, long-term care, and palliative care.

Most countries (89%) reporting to WHO’s Global Dementia Observatory say they provide some community-based services for dementia, but provision is higher in high-income countries than in low- and middle-income countries. In low- and middle-income countries, two-thirds of dementia care costs are attributable to informal care as opposed to 40% in richer countries. 

Dementia research 

High costs of research and development coupled with several unsuccessful clinical trials have led to a decline in new efforts, the report found.

However, countries like Canada and the US have recently allocated funds towards more dementia research. The US increased its annual investment in Alzheimer’s disease research from US$ 631 million in 2015 to an estimated $ 2.8 billion in 2020. 

“To have a better chance of success, dementia research efforts need to have a clear direction and be better coordinated,” said Dr Tarun Dua, Head of the Brain Health Unit at WHO. “This is why WHO is developing the Dementia Research Blueprint, a global coordination mechanism to provide structure to research efforts and stimulate new initiatives.” 

Future research efforts, states the report, should focus on the people living with dementia and their carers and family.

 

Image Credits: WHO/I. Montilla, WHO/Cathy Greenblat.

Dr Chikwe Ihekweazu, head of the new WHO Hub for Pandemic and Epidemic Intelligence, speaking at the hub’s launch in Berlin.

Monkey Pox, Lassa Fever, Yellow Fever, Cerebrospinal Meningitis, and COVID-19 are some of the epidemics that Dr Chikwe Ihekweazu has addressed as head of the Nigeria Centre for Disease Control (NCDC).

Now, however, Ihekweazu’s repertoire of disease experience is about to expand exponentially, following his appointment as the head of the World Health Organization’s (WHO) new Hub for Pandemic and Epidemic Intelligence.

The hub was formally launched in Berlin on Wednesday in event co-hosted by WHO Director General Dr Tedros Adhanom Ghebreyesus and outgoing German Chancellor Angela Merkel.

The aim of the hub is to create the tools and data needed to enable countries to better “prepare, detect and respond to pandemic and epidemic risks,” according to WHO.

Ihekweazu, an infectious disease epidemiologist, is widely credited with modernising and transforming the Nigerian CDC to address the multitude of epidemics that Africa’s most populous country faces every year.

Believing in themselves

Speaking at the hub’s launch, Ihekweazu said that his biggest lesson from working at the NCDC was empowering its staff to believe in themselves.

“I met a group of people that really didn’t believe that they could do what was expected of them,” he said.  “By believing that they could stretch a little bit beyond what they would normally do, they started trying. And once they started trying and succeeding in small steps, they started believing that they could do more.”

He frankly admitted that the new WHO hub faces “a lot of uncertainty, and sometimes a lack of definition in terms of where exactly we want to go.”

Said Ihekweazu: “We have to be comfortable with that uncertainty, but really look for people that would believe the vision and once they believe the vision and … the threats that we face, that we can work together, despite some of the political challenges, despite some of the economic differences between countries.” 

Ihekweazu, who will now be based in Berlin, has a German mother and Nigerian father. He has a Master’s in Public Health degree from the Heinrich-Heine University in Dusseldorf and worked for the Robert Koch Institute in Berlin, Germany’s national global health research and surveillance hub.

Ihekweazu was appointed as CEO of the NCDC in August 2016, just as the devastating, two-year West African Ebola epidemic was finally coming to an end.  Although the epidemic struck hardest in Guinea, Liberia and Sierra Leone, bruising Nigeria with only about 20 cases, it underscored the immense risks faced by the country of more than 210 million people, where many of the 32 200 health facilities were ill-equipped to address basic health needs.

Ihekweazu spent his first months in office assessing the country’s readiness for other future epidemics – including a range of threats that could potentially be as deadly as Ebola, or even less so, but more infectious, as COVID has proven to be.

“I met Disease Surveillance and Notification Officers without laptops and laboratory technicians with no laboratories,” Ihekweazu wrote in a blog a few months after his appointment.

“Motivated and properly equipped health workers at the frontline of our surveillance work are critical to our disease control efforts. An effective public health laboratory is critical. Proper supply chain management for our medical supplies will ensure that we are always ready for any outbreak.”

Sleepless nights about Ebola

He admitted to having sleepless nights, asking himself: “If we were to have another case of Ebola in Nigeria, would we have the laboratory infrastructure to make a timely diagnosis to recognise it and prevent a large outbreak?”

In June 2017, a WHO team conducted a Joint External Evaluation (JEE) to test Nigeria’s capacity to implement the International Health Regulations (IHR), a set of mandatory laws aimed at ensuring that member states are able to prevent the spread of diseases.

Nigeria’s JEE scorecard was littered with red warnings, and the country’s overall score was 39 percent. But the JEE highlighted the positive role of the NCDC, describing it as “among the most noteworthy best practices observed in Nigeria”.

It described the NCDC’s outbreak investigations as “robust and timely”, and praised the Emergency Operations Centre (EOC) activated to respond to outbreaks, and its call centre, which the public uses extensively during public health emergencies.

By 2018, Ihekweazu had doubled the staff of the NCDC and set up laboratories across the country.

In November 2020, the NCDC and external evaluators conducted a midterm JEE and the country’s score had increased to 46%, bringing them from the “not ready” category into the “work to do” category, according to Prevent Epidemics.

New fire

“The NCDC has given the nation a sense of pride,” said Dr Ifeanyi Nsofor, Director of Policy and Advocacy for Nigeria Health Watch, a civil society organisation that advocates for improved health for Nigerians.

In an interview with me a few years ago, Nsofor described Ihekweazu as being “really instrumental in the changes” made to Nigeria’s approach to fighting epidemics.

“He is the new fire in the agency. It is no longer business as usual. He has brought in the right way of doing things. He has the knowledge, the personality and the networks.”

After Ebola, one of Ihekweazu’s next challenges was to deal with Lassa Fever, a viral hemorrhagic fever from the same family as Ebola spread by rats that is endemic in West Africa.

During an outbreak in 2018, the NCDC proved that it was able to act fast to save lives, which Nsofor attributes to the center’s ability to “conduct research while an outbreak was happening”.

“There was real-time gene sequencing of the virus and the NCDC was able to establish that there was not just one strain of the virus but different strains. This meant a different diagnostic process,” said Nsofor.

His new appointment has been praised across Twitter by health experts and ordinary Nigerians.

Speaking at the launch of the new pandemics hub, WHO’s Tedros said of Ihekweazu: “he brings a wealth of experience, and will serve a dual role as head of the hub here in Berlin and as Assistant Director-General for health emergency intelligence in Geneva.”

 

WHO Director-General Dr Tedros Adhanom Ghebreyesus addresses the launch of the WHO Pandemic Intelligence Hub.

The only thing that moves faster than viruses is data, experts noted at Wednesday’s launch of the World Health Organization (WHO) Hub for Pandemic and Epidemic Intelligence in Berlin.

The aim of the hub is to work with partners to “create the tools and data needed to enable countries to prepare, detect and respond to pandemic and epidemic risks”, according to the WHO.

It named Dr Chikwe Ihekweazu, Director-General of Nigeria’s Centre for Disease Control, as new head of the hub, and WHO Assistant Director-General for health emergency intelligence in Geneva.

READ about Dr Chikwe Ihekweazu here

WHO Director-General Dr Tedros Adhanom Ghebreyesus said that the hub was about ”leveraging innovation in data science, harnessing the power of artificial intelligence, quantum computing and other cutting edge technologies and fostering greater sharing of data and information between communities and countries”. 

“No single institution, or nation can do this alone. That’s why we have coined the term collaborative intelligence to sum up our collective mission,” Dr Tedros told a media briefing after the launch.

“This hub will bring together scientists, innovators, policymakers, and civil society representatives from around the world to work across borders and disciplines, of course, the ultimate goal is not just to develop new toys, it’s to save lives.”

According to the WHO, the hub will work to:
* Enhance methods for access to multiple data sources vital to generating signals and insights on disease emergence, evolution and impact;
* Develop state of the art tools to process, analyse and model data for detection, assessment and response;
* Provide WHO, Member States, and partners with these tools to underpin better, faster decisions on how to address outbreak signals and events; and
* Connect and catalyze institutions and networks developing disease outbreak solutions for the present and future.

Dr Tedros, who cut a ribbon with German Chancellor Angela Merkel to inaugurate the hub, credited Merkel with the vision to set up the institution, and later in the event awarded her with the WHO Global Leadership Award in recognition of her “outstanding contribution to global health”.

WHO Director-General Dr Tedros Adhanom Ghebreyesus giving German Chancellor Angela Merkel the WHO Global Leadership Award

The catalyst for the hub, said Tedros, was Merkel’s question: “How can we react faster and avoid the needless suffering and death of the COVID-19 pandemic in future?”

The hub will be supported by the German government, already the biggest contributor to the ACT Accelerator, and international donors.

“To effectively prevent future pandemics, we need more transparency, more real-time data sharing and experiences at all levels from different sectors,” said German health minister Jens Spahn.

“Once again, I call on China to finally become fully cooperative and to make the examination of the origin of the SARS-CoV2 virus transparent to the international community. That’s important to learn for future pandemics,” added Spahn. 

Ready, fast and agile

Dr Michael J Ryan, Executive Director WHO Health Emergencies Programme, saidd that he had spent most of his professional life trying to protect people from epidemics and other health emergencies.

“In my experience, we need three really important, critical things to be effective in response. We must be ready, we must be fast and we must be agile,” said Ryan.

“We need to be able to predict, prepare and plan for what may happen. We must be able to detect, assess and react to what is happening around us the earliest possible signal of an event, and then we must be able to adapt quickly to the realities of an evolving event, which is never exactly what you plan for or expect,” he added.

Describing as prescient the remark that the only thing that could move faster than viruses was data, Ryan said a more effective response to pandemics could be honed through “better data analytics and insights to improve the speed and adaptability of our response”.

Ursula von der Leyen, President of the European Commission.

As the European Union (EU) announced on Tuesday that 70% of its adults had been fully vaccinated against COVID-19, it recommended reimposing restrictions on travellers from the US, Israel, Kosovo, Lebanon, Montenegro, and North Macedonia.

On 8 June, the six were included on an EU Council list of “safe countries” identified for the relaxing of non-essential travel restrictions. But rising COVID-19 cases in these countries – alongside the US failure to lift its travel restrictions on EU citizens – were behind their removal, which was announced in a press release on Monday.

The EU Council recommendation is not binding on member states, who can determine what restrictions to impose.

The EU also recommended the gradual lifting of restrictions on a number of new countries including Canada, Japan, South Korea and the Ukraine  – as well as China, “subject to confirmation of reciprocity”.

In early August, EU Commission president Ursula von den Leyen appealed to the US to lift its ban on travellers from Schengen states – virtually the entire EU – who have to quarantine in a third country for 14 days before being allowed into the US.

In the US, 63% of adults are fully vaccinated and COVID-19 cases continue to rise amid a politicised battle over vaccines and masks, with Republican Party supporters markedly less likely to be vaccinated than Democrats. 

Welcoming the fact that 70% of adults were vaccinated, Von den Leyen said that more needed to be done to assist other countries to vaccinate citizens.

“The EU is already doing a lot. We are exporting, donating vaccines to our partners and we are the lead contributor to COVAX but more needs to be done. We will only end this pandemic if we defeat it in every corner of the globe,” said Von der Leyen.

However, there are substantial differences between member states. Only 20% of Bulgarian and 32% of Romanian adults are fully vaccinated. In contrast, Malta has vaccinated 90% of its population and Portugal, 83,5%, according to the European Centre for Disease Prevention and Control (ECDPC).

Image Credits: Twitter – Ursula von der Leyen.

The World Health Organization (WHO) has not listed the SARS-CoV2 C.1.2 variant discovered in South Africa as either a variant of interest or of concern, and it does not appear to be increasing in circulation.

This follows an alert about the variant that was issued on Monday by the South African National Institute for Communicable Disease (NICD), and a recent pre-print article that reported “the identification of a potential variant of interest assigned to the PANGO lineage C.1.2”.

Maria Van Kerkhove, WHO’s lead on COVID-19, tweeted on Monday that the variant “did not seem to be increasing in circulation but we need more sequencing to be conducted and shared globally. Delta appears dominant from available sequences”.

According to the NICD, the variant has been “detected in all provinces in South Africa at relatively low frequency (up to ~2% of genomes)” between May, when it was first detected, and August. By far the majority of COVID-19 cases in the country are due to the Delta variant.

“While the C.1.2 lineage shares a few common mutations with the Beta and Delta variants, the new lineage has a number of additional mutations,” according to the NICD.

“While some of the mutations in the C.1.2 lineage have arisen in other SARS-CoV-2 variants of concern or variants of interest, we are being cautious about the implications, while we gather more data to understand virus of this lineage.”

The preprint article notes that C.1.2 has “concerning constellations of mutations”. These include “multiple substitutions (R190S, D215G, E484K, N501Y, H655Y and T859N) and deletions (Y144del, L242-A243del) within the spike protein, which have been observed in other VOCs and are associated with increased transmissibility and reduced neutralization sensitivity”.

However, the article notes: “Of greater concern is the accumulation of additional mutations (C136F, Y449H and N679K) which are also likely to impact neutralization sensitivity or furin cleavage and therefore replicative fitness.”

 

Professor Tulio de Oliveria of the KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), one of the authors, said that the scientists had decided to publish the pre-print as they observed “the C.1.2 persistence in South Africa and is now in another 10 countries”. 

Acknowledging that “it is early days as only 95 genomes have been published”,  we have found that “in this pandemic is share info quicker than later”, said De Oliveria.

De Oliveria said that C.1.2 has 14 mutations in the spike protein “including three mutations at the receptor-binding motif, the Y449H, E484K, and N501Y” and that two of the mutations have been found in variants of concern Alpha, Beta, and Gamma.

It has since been found in Africa, Europe, Asia and Oceania.

“Based on our understanding of the mutations in this lineage, partial immune escape may be possible, but despite this, vaccines will still offer high levels of protection against hospitalization and death,” according to the NICD.

“We expect new variants to continue to emerge wherever the virus is spreading. Vaccination remains critical to protect those in our communities at high risk of hospitalization and death, to reduce strain on the health system, and to help slow transmission.”

The WHO defines a “variant of concern” as one that enables “an increase in transmissibility or detrimental change in COVID-19 epidemiology, or an increase in virulence or change in clinical disease presentation; or a decrease in effectiveness of public health and social measures or available diagnostics, vaccines, therapeutics”. 

Meanwhile, a WHO “variant of interest” is characterised by “genetic changes that are predicted or known to affect virus characteristics such as transmissibility, disease severity, immune escape, diagnostic or therapeutic escape; and identified to cause significant community transmission or multiple COVID-19 clusters, in multiple countries with increasing relative prevalence, alongside increasing number of cases over time, or other apparent epidemiological impacts to suggest an emerging risk to global public health”.

The first two girls ever vaccinated with the malaria vaccine RTS,S in Ghana.

In the midst of the tragedy and turmoil caused by the COVID-19 pandemic, it is gratifying to see work continuing in Africa to find new ways of fighting malaria, a very old disease that has been a formidable foe for thousands of years and still kills 400,000 people every year, most of them African children under five years old.

Scientists from the London School of Hygiene and Tropical Medicine and their colleagues at the Institut de Recherche en Sciences de la Santé in Burkina Faso and the University of Bamako in Mali recently published results from a phase 3 trial that involved the world’s first and only malaria vaccine (referred to as RTS,S).

The new evidence from Mali and Burkina Faso shows that RTS,S – which is also being introduced in Ghana, Kenya and Malawi in a landmark pilot – could be an even more valuable tool than originally expected. And those of us involved in the fight against malaria are certainly eager for good news. 

Working in areas where malaria surges during the rainy season, the researchers report a dramatic reduction in malaria illness and deaths among young children who received the RTS,S vaccine just before the rains began. They found the vaccine worked as well as the standard prevention practice in these regions, known as seasonal malaria chemoprevention (SMC), which involves administering treatment doses of common antimalaria drugs monthly during the rainy season, usually through a door-to-door campaign. 

This is an important finding. SMC is a resource-heavy intervention, and in some settings, an annual pre-season single dose of a vaccine could be an attractive alternative. 

Striking results

However, the most striking results occurred in the group of some 1700 children who received both interventions – the medications and the vaccine. They experienced a 60% – 70% additional reduction in severe disease and hospitalizations compared to the already impressive stand-alone interventions – the prevention drugs or the RTS,S vaccine – and also more than a 70% reduction in deaths from malaria. Equally important: the combination was found to be safe and well tolerated. 

I was one of a group of African Ministers of Health in June 2016 who served on the Board of Gavi, the global vaccine alliance, and passionately supported the funding for a RTS,S pilot to learn more about its public health potential. These new results are heartening. 

RTS,S is the first malaria vaccine shown to reduce malaria and life-threatening severe malaria in young children. Approximately 2.1 million doses of the vaccine have been provided and more than 750,000 children have received their first vaccine dose through the pilot programme where malaria risks occur year-round. 

Results from the pilot programme also indicate strong community demand for the malaria vaccine as well as the capacity of childhood vaccination to deliver it. This new study in Burkina Faso and Mali provides additional evidence of RTS,S safety and effectiveness. 

Just before the COVID-19 pandemic arrived, Africa’s fight against malaria was stalling at what the World Health Organization (WHO) called an “unacceptably high level of deaths. Regaining momentum in the malaria fight will require new tools, especially with existing preventive interventions threatened by emerging insecticide resistance. 

New tools to fight malaria are especially needed in countries like Mali and Burkina Faso, located in a region known as the African Sahel – a semi-arid ribbon of land that spans the continent from Senegal to Sudan. There, the danger of malaria flares dramatically with the arrival of the rainy season. Today, six of the ten African countries singled out by the WHO as requiring “high impact” malaria interventions are in the Sahel, where malaria remains a primary cause of childhood death despite substantial reductions in malaria achieved through a combination of SMC and insecticide-treated nets (ITNs). 

Seasonal influence

Through the development of the RTS,S vaccine over the last 30 years, scientists have discovered that the protective efficacy of RTS,S is particularly high in the first months following vaccination. This feature prompted researchers to study whether RTS,S could be provided strategically, just before the peak malaria season, to fight seasonal malaria transmission. 

Giving the RTS,S malaria vaccine seasonally was found to be safe and effective—and combining SMC with the vaccine was especially powerful—and could expand the options available for fighting malaria. 

In October, global advisory bodies for immunization and malaria will convene to review available RTS,S evidence and consider a potential WHO recommendation for wider use of the vaccine across Africa. 

If WHO recommends the vaccine for wider use, African governments should be prepared to seize on the life-saving opportunity. They must be ready to make smart and strategic decisions to deploy this vaccine while continuing to promote the use of other proven malaria interventions to maximise impact. 

We have seen in COVID-19 what the global health community can accomplish when it comes together to fight a killer disease. It would be a welcome turn of events to see Africa emerge from the pandemic with a new tool to take on the old foe of malaria with renewed vigour to get progress in malaria control back on track.  

Dr Kesete Admasu is CEO of Big Win Philanthropy, former CEO of the RBM Partnership to End Malaria, and former Minister of Health in Ethiopia. 

Dr Kesete Admasu

Image Credits: WHO/Fanjan Combrink.

Air pollution in Mashhad, Iran

When Algerian service stations stopped providing leaded petrol last month, this marked the successful end to a global campaign to eliminate this “major threat to human and planetary health”.

Celebrating the official end of the use of leaded petrol on Monday, United Nations Secretary-General Antonio Gutteres said that when the global campaign to eliminate the use of tetraethyllead (TEL) as a petrol additive started in 2002, 117 countries were still using TEL.

“Today, there are none. Lead in fuel has run out of gas, thanks to the cooperation of governments in developing nations, thousands of businesses, and millions of ordinary people,” said Gutteres in a video message to a media briefing.

“Ending the use of leaded petrol will prevent more than one million premature deaths each year from heart disease, strokes, and cancer, and protect children whose IQs are damaged by exposure to lead. This achievement again shows what we can accomplish when we work together across countries and sectors for the common good.”  

The head of the UN Environment Programme (UNEP), which led the campaign, said that the same approach to TEL elimination should also be applied to the phasing out of fossil fuels.

UNEP Executive Director Inger Andersen told the media briefing that companies used TEL to improve engine performance but this “was emitted in exhaust fumes, causing airborne pollution, and soil pollution”, later damaging the catalytic converters that reduced up to 95% of the common air pollutants. 

“Basically, industry rushed to adopt the first and cheapest technology that worked despite its grave implications for environmental health and for the environment, while ignoring sustainable and clean technologies. And that kind of sounds familiar,” said Andersen.

“But in the global response to leaded fuel shows that humanity can learn from and fix mistakes that we made,” she added.

The campaign’s success rested on an innovative public-private partnership, the Partnership for Clean Fuels and Vehicles, with over 75 members.

The campaign had to overcome resistance from companies producing the lead additive by promoting investments to replace lead that maintained the same octane levels and were not costly, she said.

“The success we celebrate today provides some clear lessons on dealing with [current] environmental challenges lessons,” added Andersen.

These included the importance of independent science, free media, clear goals, interventions that stressed the benefits for people, and high-level political commitment and leadership. 

“Now we must apply these lessons in developing better vehicle standards to deal with carbon dioxide emissions from the global transport sector as we transition away from fossil fuels, in ridding the world of single-use plastics, in restoring forests and other degraded ecosystems, in protecting wildlife,” said Andersen.

“We can do this together in partnership but we will only succeed if we work together as we have done on to unleaded fuels.”

UNEP Executive Director Inger Andersen

Cleaner used cars for Africa

Beninese politician Luc Gnacadja, former Executive Secretary of the UN Convention to Combat Desertification, told the media briefing that airborne lead pollution in his country’s cities had topped the list of environment-related health issues in 2000

“The socio-economic costs of leaded gasoline in only four of our major cities was estimated to be equivalent to 1.2% of our GDP in 2013,” said Gnacadja, who described the elimination of leaded fuel as “an outstanding success”.

However, Gnacadja said that poor-quality used vehicles imported by African countries were contributing to “high and rising urban pollution and high road accidents and fatalities”. 

“It is projected that, in the next two decades, the number of light-duty vehicles in Africa will triple, and the demand for oil will double,” he said.

Only two African countries had made moves to ensure that imported used vehicles “meet the minimum environment and safety requirements”, but if such measures were uniformly adopted across the continent, this could make African vehicles up to 80% cleaner, and reduce accidents by up to 50%,” he concluded.

Image Credits: Flickr, Mohammad Hossein Taaghi.

Although the World Health Organization (WHO) has issued technical guidelines for the development of digital COVID-19 ‘vaccine certificates’, it has stressed that these should not be a prerequisite for international travel.  

At the release of the technical guidelines last Friday (27 August), the WHO stated that it “does not support the requirement of proof of COVID-19 vaccination in order to travel”, citing that vaccines were not yet widely available in many countries.

“In some situations, however, depending on the risk assessment of the countries concerned, information about vaccination against COVID-19 may be used to reduce requirements for quarantine or testing upon arrival,” it added in a media statement.

“Historically, paper-based vaccination records have presented many challenges – such as the possibility of losing or damaging the card, or even the possibility of fraud. The proposed digital solutions are designed to address these challenges.”

In mid-July, the International Health Regulations Emergency Committee (IHR EC) advised the WHO to “expedite the work to establish updated means for documenting COVID-19 status of travellers, including vaccination, history of SARS-CoV-2 infection, and SARS-CoV-2 test results”.

It also advised that WHO member states recognise “all COVID-19 vaccines that have received WHO Emergency Use Listing in the context of international travel”. 

Adaptation of ‘yellow card’?

The WHO has proposed that, in the absence of digital certificates to record COVID-19 vaccinations, the International Certificate of Vaccination and Prophylaxis (ICVP) could be updated to include COVID-19 vaccinations. The ICVP, known as the “yellow card”, is used internationally mostly to show that travellers have had yellow fever vaccines.

However, the technical guidance sets out how to create a signed digital version of a vaccination record for COVID-19 “based on a core data set of key information to be recorded, and an approach for the digital signature”. 

It provides member states with a baseline set of requirements for a compliant digital system that is a “software-agnostic”  starting point for member states, who can use it to develop their own systems based on whichever format best suits their needs, from a paper card with a barcode or QR code stickers, to a smartphone application. 

The guidance stresses that the certificates should “never create inequity due to lack of access to specific software or technologies”, and must be “applicable to the widest range of use cases, catering to many different levels of digital maturity between implementing countries”. 

However, it identifies the “minimum requirements” for the introduction of digital certificates, namely that:

  • The ethical and privacy implications and potential risks are properly assessed
  • There are policies to establish their appropriate use, data protection and governance
  •  A digitally signed electronic version of the data about a vaccination event must exist
  • Anyone who has received vaccination should have access to proof of this – either as a traditional paper card or an electronic database.
  • If a paper vaccination card is used, it should be associated with a health certificate identifier (HCID) in a format that can be read by both people and machines (eg bar codes)
  • A digital registry should exist to store the information associated with the HCID and generate data about a vaccination.

International verification

The guideline includes a section on how digital vaccine ‘passes’ could be developed to enable them to be verified in foreign jurisdictions, such as for international travel. In these cases, international bodies should be able to access a country’s national registry, using digital cryptographic processes, to check whether the HCID barcode on paper is valid and hasn’t been revoked or altered.

A number of international COVID-19 ‘vaccine passes’ are already in use. The European Union started using its digital COVID-19 certificate on 1 July to facilitate travel in the EU.

The EU certificate is based on a QR code that “contains necessary key information such as name, date of birth, date of issuance, relevant information about vaccine/ test/ recovery and a unique identifier”.This data is not retained by the countries a person visits. 

There is no national system in the US other than a card issued by the Centers for Disease Control (CDC), but some states and even cities such as New York have developed apps to enable fully vaccinated people to verify their status, which is often necessary to enter various public gatherings.

There have been protests through Europe against ‘vaccine passports’, mostly by libertarians and anti-vaxxers opposed to any form of compulsory vaccination.

 

Image Credits: UNICEF/Kokoroko, Wikimedia Commons: Nemo.